Cloud DX: Pushing the Boundaries of Medical Device Technology

January 1, 2022

Precision vital sign monitoring equipment, software and mobile apps that cost less

Cloud DX combines core competencies in biomedical hardware engineering, cloud-based medical device architecture, algorithm-based result generation, regulatory approval experience, and internationally ISO certified quality management, brought together to create a new category of medical device: the medically accurate, consumer/clinical vital sign platform. Cloud DX is a first-mover in the race to combine clinical-grade data collection with a consumer-friendly user experience.

They are pushing the boundaries of medical device technology, with smart sensors, ease of use, cloud diagnostics, artificial intelligence, and incredible design.

Problems they solve

High Cost:
Remote Patient Monitoring equipment is too expensive for a wide scale. Cloud DX Connected Health can be purchased on a monthly op-ex basis, often paid for by Medicare and/or private reimbursement. Cloud DX is committed to reducing the cost of vital sign monitoring.

Complexity:
Remote Patient Monitoring systems can be complicated to use, discouraging older patients. Cloud DX Connected Health Kits come with all devices pre-paired and an Android tablet already connected so that the whole system “just works” out of the box.

Integration:
Remote Patient Monitoring data is rarely integrated into the EMR. Cloud DX Connected Health is already integrated into several popular EMRs and our secure cloud-based APIs make integration easy.

For more information on Cloud DX Inc. (TSX.V: CDX) please click the request investor info button.

You might also like

Healthcare
Lexaria Bioscience: Revolutionizing GLP-1 Drug Delivery with Patented Oral Platform

Lexaria Bioscience is setting new standards in drug delivery with its patented DehydraTECH™ oral technology, optimizing absorption for GLP-1 and other high-demand drugs.

Healthcare
Lexaria Bioscience: Advancing GLP-1 Drug Delivery with DehydraTECH™ Technology

Lexaria Bioscience’s DehydraTECH™ technology aims to redefine oral drug delivery, focusing on faster absorption and improved efficacy, with a promising impact on the GLP-1 pharmaceutical market.

Content Broadcast on: BNN Bloomberg, CNBC, Bloomberg, FOX Business News, BIZTV, Reuters, The Globe and Mail, YouTube and more!